Passage Bio, Inc. (PASG) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
August 4, 2022 7:00 AM EDTAdvanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee Presented encouraging longer-term clinical and biomarker data from Cohort 1 in Imagine-1 study at ASGCT; interim safety and biomarker data for Cohorts 2 and 3 expected in 2H22Received IND clearance for Phase 1 clinical program of PBML04 for metachromatic leukodystrophyEnded 2Q22 with strong cash position; cash on hand to fund operations into 2Q24Management to host conference call today at 8:30 a.m. ET... More
